Literature DB >> 11035908

Osteoporosis and osteoporotic fractures in men: a clinical perspective.

D Vanderschueren1, S Boonen, R Bouillon.   

Abstract

The lifetime risk of any fracture of the hip, spine or distal forearm in men aged 50 years has been estimated to be 13%, compared with 40% in women. Although the overall incidence of osteoporosis is less in men than in women, the disease still represents an important public health problem. In particular, hip fractures are associated with substantial mortality and morbidity, even more so than in women. In male patients presenting with osteoporotic fractures, major causes of skeletal fragility, such as hypogonadism, glucocorticoid excess, primary hyperparathyroidism and alcohol abuse, can often be identified. In as many as 50% of osteoporotic men, however, no aetiology can be found: these men suffer from a syndrome commonly referred to as idiopathic osteoporosis, which is presumably related to some type of osteoblast dysfunction. Recent evidence indicates that the loss of skeletal integrity in ageing men may be partially related to endocrine deficiencies, including vitamin D, androgen and/or oestrogen deficiency. While the consequences of vitamin D or oestrogen deficiency in women have been well established, the skeletal impact of these (partial) age-related deficiencies in men remains to be clarified. Osteoporosis in elderly men is a multifactorial disease, as it is in women. The prevention of osteoporosis should therefore focus not only on increasing the bone strength, but also on decreasing the risk of falls. However, the prevention and therapy of osteoporotic disorders in men are virtually unexplored. To date, the use of specific osteoporotic drugs in osteoporotic men is still based on reasonable but untested assumptions. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11035908     DOI: 10.1053/beem.2000.0075

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  6 in total

1.  Long-term culture in dexamethasone unmasks an abnormal phenotype in osteoblasts isolated from osteoporotic subjects.

Authors:  L G Rao; T M Murray; J N Wylie; R J McBroom; M Kung Sutherland
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

Review 2.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

3.  CoQ10 suppression of oxidative stress and cell senescence increases bone mass in orchiectomized mice.

Authors:  Xuan Wu; Shuo Liang; Xingyu Zhu; Xiaotao Wu; Zhan Dong
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

4.  The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.

Authors:  Peter Schwarz; Niklas Rye Jorgensen; Leif Mosekilde; Peter Vestergaard
Journal:  J Osteoporos       Date:  2011-06-24

5.  Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60-75 Years.

Authors:  Aleksandra Rył; Aleksandra Szylińska; Alina Jurewicz; Andrzej Bohatyrewicz; Tomasz Miazgowski; Iwona Rotter
Journal:  Int J Environ Res Public Health       Date:  2019-12-22       Impact factor: 3.390

Review 6.  Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.

Authors:  Raja Bobba; Jonathan D Adachi
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.